Vasgen Limited Attends 2012 Genesis Conference 13/12/2012
Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports its participation at the recent 2012 Genesis Conference in London UK.
Organised by One Nucleus and SCRIP Intelligence, the 2012 conference focused on the theme of “innovative strategies to bridge the R & D gap.” Dr Yatin Patel, COO and co-founder of Vasgen said: “This year’s Genesis Conference provided an excellent opportunity for our new company to meet with other companies in the life science space. It was extremely encouraging to see so many novel technologies coming to market and to meet with potential future partners.”
-Ends-
Notes to Editors
Vasgen limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMPTM, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149